Characteristics and therapies of the discovery and replication cohorts
| Characteristic | Discovery (n=70) | Replication (n=34) | p Value |
|---|---|---|---|
| Age (years) | 31.9±10.9 | 35.4±11.9 | 0.16 |
| Male | 45 (64%) | 23 (68%) | 0.74 |
| Genotype | 0.22 | ||
| Homozygous F508del | 26 (37%) | 12 (35%) | |
| Heterozygous F508del | 29 (41%) | 19 (56%) | |
| Other | 15 (21%) | 3 (9%) | |
| BMI (kg/m2) | 23.1±3.6 | 23.9±3.6 | 0.34 |
| FEV1 (% predicted) | 74.1±28.0 | 69.9±23.8 | 0.51 |
| Sputum microbiology: | |||
| MSSA | 35 (50%) | 18 (53%) | 0.82 |
| MRSA | 9 (13%) | 3 (9%) | 0.53 |
| Pseudomonas aeruginosa | 32 (46%) | 19 (56%) | 0.26 |
| Stenotrophomonas maltophilia | 2 (3%) | 2 (6%) | 0.52 |
| Burkholderia cepacia complex | 8 (11%) | 7 (21%) | 0.24 |
| CF-related diabetes | 21 (30%) | 11 (32%) | 0.91 |
| Exacerbation requiring intravenous antibiotics in prior year | 23 (33%) | 11 (32%) | 0.99 |
| Current therapies | |||
| Inhaled antibiotics | 17 (24%) | 8 (24%) | 0.91 |
| Oral azithromycin | 26 (37%) | 13 (38%) | 0.93 |
Mean±SD or number (proportion).
BMI, body mass index; CF, cystic fibrosis; MRSA, methicillin-resistant Staphylococcus aureus; MSSA, methicillin-sensitive S. aureus.